eCite Digital Repository
Generic substitution of antiepileptics: need for a balanced view
Citation
Peterson, GM, Generic substitution of antiepileptics: need for a balanced view, Cns Spectrums, 16, (8) pp. 579-585. ISSN 1092-8529 (2011) [Refereed Article]
![]() | PDF Restricted - Request a copy 196Kb |
Copyright Statement
Copyright © 2011 MBL Communications
Official URL: http://cmepsychcast.mblcommunications.com/
DOI: doi:10.1017/S109285291200034X
Abstract
There is considerable interest and debate concerning the place of generic substitution, especially relating to antiepileptic drugs (AEDs). Sadly, one of the causes of the ongoing debate is confusion, often intentionally fueled by the pharmaceutical industry among health professionals and patients regarding the regulatory determination of bioequivalence. Few understand the correct definition. It is often erroneously stated that to be considered bioequivalent there is an allowed difference in the extent and rate of absorption of 80% to 125% between a generic drug product and the branded standard. This is false and implies there is a wide leniency allowed, with varying clinical outcomes probable. This myth needs to be countered to reassure the safety of patients. A balanced review of the issues surrounding the generic substitution of AEDs is presented.
Item Details
Item Type: | Refereed Article |
---|---|
Research Division: | Biomedical and Clinical Sciences |
Research Group: | Pharmacology and pharmaceutical sciences |
Research Field: | Clinical pharmacology and therapeutics |
Objective Division: | Health |
Objective Group: | Clinical health |
Objective Field: | Clinical health not elsewhere classified |
UTAS Author: | Peterson, GM (Professor Gregory Peterson) |
ID Code: | 71695 |
Year Published: | 2011 |
Web of Science® Times Cited: | 2 |
Deposited By: | Pharmacy |
Deposited On: | 2011-08-02 |
Last Modified: | 2017-08-14 |
Downloads: | 1 View Download Statistics |
Repository Staff Only: item control page